KyungDong Pharm home
Prescription Medicines

Acellbron Cap.

Product Category
Respiratory Medicines
Active Ingredients
Acebrophylline
Appearance
A capsule with a gray cap and white body, containing white to off-white powder.
Reimbursement Code
648105050
View Regulatory Information on the MFDS Portal ↗
1. Ingredient content
Of 1 capsule
- Active ingredient: Acebrophylline (KP) ······················ 100mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, capsule, talc

2. Effectiveness
Acute and chronic respiratory diseases caused by airway obstruction and mucus secretion disorders:
Acute/chronic bronchitis, bronchial asthma, sinusitis, dry rhinitis

3. Dosage and dosage
Adults: Acebrophylline is administered orally at a dose of 100 mg twice a day.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug, its components, or other xanthine drugs
2) Patients with hypersensitivity to ambroxol
3) Patients with acute myocardial infarction
4) Patients with low blood pressure
5) Patients with severe liver or kidney impairment
6) Nursing mothers
7) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with heart disease, coronary circulatory failure, and congestive heart failure
2) Obese patients
3) Patients with a history of epilepsy
4) Patients with stomach and duodenal ulcers
5) Patients with hyperthyroidism
6) Elderly people
7) Pediatrics
8) Patients with high blood pressure
9) Patients with severe hypoxemia
10) Patients with chronic obstructive pulmonary disease
11) Patients with liver and kidney disorders
12) Women who are pregnant or may be pregnant

3. Adverse reactions
1) There are cases of temporary nausea and dizziness reported when taking xanthine drugs, and these effects disappear when you stop taking them.
2) Digestive system: In rare cases, stomach discomfort, stomach/abdominal distension, stomach/abdominal pain, diarrhea, constipation, nausea, vomiting, hematemesis, heartburn, loss of appetite, gastroesophageal bleeding, and solar plexus pain may occur.
3) Hypersensitivity reaction: In rare cases, rash, hives, urticaria-like erythema, itching, facial swelling, difficulty breathing, and increased body temperature accompanied by cold may occur. In such cases, discontinue administration.
4) Respiratory system: Purulent rhinitis and tachypnea accompanied by an increase in white blood cells may occur.
5) Others: In rare cases, numbness in the mouth, numbness in the arms, headache, excitement, insomnia, tachycardia, extrasystoles, hyperrelaxation, hypotension, and sometimes albuminuria and hyperglycemia may occur.
6) As a result of a post-marketing survey conducted on 806 people over 6 years in Korea, the frequency of adverse reactions was reported to be 1.2% (9 cases/760 cases) regardless of causal relationship, and the types were 0.4% (3 cases) of stomach discomfort, 0.4% (3 cases) of digestive problems, and 0.4% (3 cases) of nausea.

4. General precautions
1) Although the ingredients of this drug are not toxic to animals, it should be taken into account that xanthine-based drugs can often be toxic at high blood concentrations.
2) Factors such as high age, alcoholism, congestive heart failure, chronic obstructive pulmonary disease, co-infection, and impaired liver and kidney function may reduce the clearance of this drug, and in this case, be careful because blood concentration may increase even if you take the recommended dose.

5. Interaction
1) When used together with drugs such as erythromycin, cephalexin, oxytetracycline, oleandomycin, lincomycin, cimetidine, allopurinol, quinolone antibiotics, oral anticoagulants, and clindamycin, the blood concentration of this drug may increase, so the dose of this drug should be reduced if necessary.
2) When used with furosemide, the diuretic effect may be increased, and when used with reserpine, it may cause tachycardia.
3) If this drug is used together with barbiturates or phenytoin, or if a patient who smokes takes this drug, the blood concentration of this drug may decrease.
4) When used in combination with other xanthine drugs or central nervous system stimulants, excessive central nervous stimulating effects occur, so do not co-administer with these drugs.
5) Caution is required when using with ephedrine or other sympathomimetic bronchodilators.

6. Administration to pregnant and lactating women
1) Although no malformations have been reported, it should not be used in the first month or end of pregnancy, except in cases where it may be fatal to the pregnant woman due to untreated asthma. There have been no reports of adverse reactions to fetal development, but like other drugs, this drug is not recommended during pregnancy.
2) The effect during lactation has not been established, so nursing mothers should not take this drug.

7. Administration to elderly people
In general, elderly people have reduced physiological function, so they should be careful about reducing their intake.

8. Administration to children
When administering this drug to children, administer with caution.

9. Treatment in case of overdose
There have been no reported cases of overdose, but overdosage can cause general tonic-clonic seizures and severe ventricular arrhythmias. If systemic convulsions do not occur due to overdosage, laxatives and activated charcoal are administered to induce vomiting. If generalized nervous system seizures occur, oxygen is supplied to measure respiratory efficiency, diazepam is administered intravenously, adequate fluids are supplied, and blood pressure is monitored. If treatment is necessary, it should be restarted at a lower dose after all symptoms of toxicity have disappeared.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Pharmaceutical equivalence test information
As a result of measuring ambroxol (active metabolite of acebrophylline) in the blood of 24 people by oral administration of 100 mg of test drug acebrophylline capsule (Yooyoung Pharmaceutical Co., Ltd.) and reference drug sulforase capsule (acebrophylline) (Hyundai Pharmaceutical Co., Ltd.) to healthy adults in a 2 When Cmax) was log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, demonstrating biological equivalence.
(Please refer to the attached document for further details)

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 capsules/bottle, 300 capsules/bottle

7. Period of use
36 months from date of manufacture